Stuff You Missed in History Class · iHeartPodcasts

Benzedrine, Pervitin, and WWII

February 16, 2026·40 min·3 clips
Pervitin was marketed as a life-enhancing supplement, leading to over-the-counter addiction in 1930s Germany.
Pervitin entered the story as a promise. It was pitched not just as a drug, but as something that could make people better, stronger, and more confident. That fit the ideology neatly. The host ties the marketing to the Nazi ideal of the superhuman, where energy became part of the sell. The ads cast a wide net. Pervitin was promoted as a stimulant for the psyche and circulatory system, with claims stretching from depression and hypotension to post-operative recovery. That last one lands strangely. The hosts linger on the thought of someone feeling too good after surgery and getting up when rest was probably the point. The humor stays dry, but it sharpens the larger issue: the danger got nowhere near enough caution. Clinical testing had happened, though the host notes those trials were far from what current standards would require. Fritz Flugel saw the split clearly. In a psychiatric hospital, he observed energy boosts that could look almost miraculous in the short term, along with increased anxiety. He reported that to Temmler. Temmler also had some awareness that Pervitin could bring unwanted effects, including habit-forming risk. The label changed, but barely. It suggested a lower dose and warned that use should happen only from time to time, with an exclamation point carrying far too much weight. That was not enough. By the end, Pervitin looks less like endurance in pill form and more like a dangerous stimulant made acceptable by ideology, marketing, and weak safeguards.

As heard by us

A sharp medical history of Pervitin's slide from promise to peril, where energy, ideology, and dependency fed one another.

Benzedrine, Pervitin, and WWII traces the uneasy shift from stimulant as medical aid to stimulant as promise of human improvement, with Pervitin carrying the clearest thread.

Read the full review in PlayNext →
Listen to the show on